[1]李莎雯.注射用甲泼尼龙琥珀酸钠联合特布他林雾化吸入治疗慢性支气管炎急性发作期的效果及安全性分析[J].医学信息,2022,35(20):77-79，83.[doi:10.3969/j.issn.1006-1959.2022.20.019]
　LI Sha-wen.Effect and Safety Analysis of Methylprednisolone Sodium Succinate for Injection Combined with Terbutaline Aerosol Inhalation in the Treatment of Acute Exacerbation of Chronic Bronchitis[J].Journal of Medical Information,2022,35(20):77-79，83.[doi:10.3969/j.issn.1006-1959.2022.20.019]
点击复制

注射用甲泼尼龙琥珀酸钠联合特布他林雾化吸入治疗慢性支气管炎急性发作期的效果及安全性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年20期
页码:
77-79，83
栏目:
论著
出版日期:
2022-10-15

文章信息/Info

Title:
Effect and Safety Analysis of Methylprednisolone Sodium Succinate for Injection Combined with Terbutaline Aerosol Inhalation in the Treatment of Acute Exacerbation of Chronic Bronchitis
文章编号:
1006-1959（2022）20-0077-04
作者:
李莎雯
（上饶市广信区血防站急诊科，江西 上饶 334100）
Author(s):
LI Sha-wen
(Department of Emergency,Guangxin District Blood Control Station,Shangrao 334100,Jiangxi,China)
关键词:
慢性支气管炎急性发作; 甲泼尼龙琥珀酸; 特布他林; 雾化治疗; 肺功能
Keywords:
Acute attack of chronic bronchitis; Methylprednisolone succinate; Terbutaline; Nebulization treatment; Lung function
分类号:
R562.2+1
DOI:
10.3969/j.issn.1006-1959.2022.20.019
文献标志码:
A
摘要:
目的 分析注射用甲泼尼龙琥珀酸钠联合特布他林雾化吸入治疗慢性支气管炎急性发作（AECB）的效果及安全性。方法 选取2019年1月-2021年6月上饶市广信区血防站急诊科收治的56例AECB患者，使用随机数字表法分为对照组（28例）与观察组（28例）。对照组采用注射用甲泼尼龙琥珀酸钠治疗，观察组采用注射用甲泼尼龙琥珀酸钠联合特布他林雾化吸入治疗，比较两组临床疗效、肺功能[呼气流量峰值（PEF）、最大通气量（MVV）、第一秒用力呼气量（FEV1）]、血气指标[血氧分压（PaO2）、二氧化碳分压（PaCO2）]、实验室指标[白细胞（WBC）、中性粒细胞计数（NEUT）、C 反应蛋白（CRP）]、不良反应。结果 观察组治疗总有效率为96.43%，高于对照组的82.14%（P＜0.05）；两组治疗后PEF、MVV、FEV1指标均升高，且观察组高于对照组（P＜0.05）；两组治疗后PaO2升高，PaCO2降低，且观察组PaO2高于对照组，PaCO2低于对照组（P＜0.05）；两组治疗后WBC、NEUT、CRP水平均降低，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为7.14%，低于对照组的28.57%（P＜0.05）。结论 注射用甲泼尼龙琥珀酸钠联合特布他林雾化吸入治疗AECB的疗效确切，可有效改善患者的肺功能及血气状态，恢复其血常规指标，减少药物不良反应。
Abstract:
Objective To analyze the efficacy and safety of methylprednisolone sodium succinate for injection combined with terbutaline inhalation in the treatment of acute exacerbation of chronic bronchitis (AECB).Methods A total of 56 patients with AECB admitted to the Emergency Department of the Guangxin District Blood Prevention Station in Shangrao City from January 2019 to June 2021 were selected and divided into a control group (28 cases) and an observation group (28 cases) by random number table method. The control group was treated with methylprednisolone sodium succinate for injection, while the observation group was treated with methylprednisolone sodium succinate for injection combined with terbutaline aerosol inhalation. The clinical efficacy, pulmonary function [peak expiratory flow (PEF), maximum ventilation (MVV), forced expiratory volume in one second (FEV1)], blood gas indexes [partial pressure of oxygen (PaO2), partial pressure of carbon dioxide (PaCO2)], laboratory indexes [white blood cell (WBC), neutrophil count (NEUT), C-reactive protein (CRP)] and adverse reactions were compared between the two groups.Results The effective rate of treatment in the observation group was 96.43%, which was higher than 82.14% in the control group (P<0.05). After treatment, PEF, MVV and FEV1 indexes in the two groups increased, and those in the observation group were higher than the control group (P<0.05). After treatment, PaO2 increased and PaCO2 decreased in the two groups, and PaO2 in the observation group was higher than that in the control group, and PaCO2 was lower than that in the control group (P<0.05). The levels of WBC, NEUT and CRP in the two groups decreased after treatment, and the levels in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 7.14%, which was lower than 28.57% in the control group (P<0.05).Conclusion Methylprednisolone sodium succinate for injection combined with terbutaline aerosol inhalation is effective in the treatment of AECB, which can significantly improve the lung function and blood gas status of patients, restore their blood routine indicators, and reduce adverse drug reactions.

参考文献/References:

[1]武金银.莫西沙星对慢性支气管炎急性发作期血气指标、内皮素-1等炎性因子水平的影响[J].安徽医药,2019,23(1):176-179.[2]EmeI’yanov AV.The therapeutic potential of inhalation glucocorticoids in patients with bronchial asthma[J].Klin Med (Mosk),2015,93(1):23-29.[3]黄薇.注射用甲泼尼龙琥珀酸钠联合米诺环素及阿奇霉素治疗小儿难治性肺炎支原体肺炎的效果[J].河南医学研究,2019,28(14):2604-2606.[4]马静.丙种球蛋白与甲泼尼龙琥珀酸钠辅助阿奇霉素冲击治疗难治性支原体肺炎患儿的临床疗效与安全性评价[J].抗感染药学,2019,16(6):1094-1096.[5]王亚君,喜雷,齐孟瑚,等.布地奈德混悬液与特布他林雾化液雾化吸入治疗学龄前儿童肺炎支原体肺炎临床分析[J].解放军预防医学杂志,2019,37(5):89-90.[6]陈楷正.布地奈德联合特布他林雾化吸入治疗小儿毛细支气管炎的疗效[J].实用临床医学,2015,16(7):67-68,75.[7]贾战文.布地奈德混悬液联合硫酸特布他林雾化吸入对喘息性支气管炎患儿康复进程的影响[J].内蒙古医学杂志,2018,50(1):77-78.[8]吴永文.甲泼尼龙琥珀酸钠对呼吸窘迫综合征患者肺功能及炎症状况的影响[J].实用临床医药杂志,2019,23(9):61-64.[9]赵红英.不同剂量甲泼尼龙琥珀酸钠治疗小儿重症支原体肺炎的临床疗效[J].儿科药学杂志,2019,25(2):34-36.[13]王焱,张兵兵.匹多莫德、孟鲁司特及甲泼尼龙琥珀酸钠联合治疗肺大叶实变性重症支原体肺炎的效果[J].中国临床研究,2018,31(8):1087-1090.[14]Prodanovic D.Novel insights into mechanisms of glucocorticoid actions and sensitivity in the airway epithelium[EB/OL].https://minerva-access.unimelb.edu.au/items/e70d4d95-d544-506b-83c3-4b46c8653fa4/full,2018-05-15/2021-12-10.[15]张惠淑,田丹虹,刘小东.氨溴索联合特布他林雾化吸入治疗慢性支气管炎急性发作的临床观察[J].辽宁医学院学报,2015,36(5):24-25,57.[16]陈宏辉.特布他林联合布地奈德雾化吸入治疗慢性支气管炎患者效果分析[J].现代诊断与治疗,2017,28(2):210-212.[17]曾维富,邹子兴.氨溴索联合雾化吸入布地奈德治疗慢性支气管炎急性发作患者的临床效果[J].中国医药科学,2016,6(22):36-38.[18]魏秀超.特布他林联合布地奈德雾化吸入治疗慢性支气管炎急性发作的临床疗效[J].临床医学,2015,35(4):63-64.[19]孙青松.特布他林联合布地奈德雾化吸入治疗慢性支气管炎效果观察[J].牡丹江医学院学报,2016,37(1):76-77.[20]杨能学.在氨茶碱和氨溴特罗基础上联用甲泼尼龙和特布他林对支气管哮喘患者的治疗作用[J].中国药房,2018,29(15):2119-2121.[21]Altonsy MO,Mostafa MM,Gerber AN,et al.Long-acting β2-agonists promote glucocorticoid-mediated repression of NF-κB by enhancing expression of the feedback regulator, TNFAIP3[J].American Journal of Physiology Lung Cellular & Molecular Physiology,2016,312(3):L358-L370.[22]Rahimi-Rad MH,Asgari B,Hosseinzadeh N,et al.Eosinopenia as a Marker of Outcome in Acute Exacerbations of Chronic Obstructive Pulmonary Disease[J].Maedica (Bucur),2015,10(1):10-13.

相似文献/References:

[1]周志明,曾文宏,叶芳芳.莫西沙星对慢性支气管炎急性发作期患者细菌清除率的影响[J].医学信息,2023,36(01):148.[doi:10.3969/j.issn.1006-1959.2023.01.031]
　ZHOU Zhi-ming,ZENG Wen-hong,YE Fang-fang.Effect of Moxifloxacin on Bacterial Clearance Rate in Patients with Acute Exacerbation of Chronic Bronchitis[J].Journal of Medical Information,2023,36(20):148.[doi:10.3969/j.issn.1006-1959.2023.01.031]

更新日期/Last Update: 1900-01-01